A randomized, multicentre, double‐blind, parallel‐group study to assess the adverse event‐related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis

References

• Kargman S., Charleson S., Cartwright M., Frank J., Riendeau D., Mancini J., et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996; 111: 445–54
   PubMed Web of Science ®Google Scholar
• Bensen W. G., Fiechtner J. J., McMillen J. I., Zhao W. W., Yu S. S., Woods E. M., et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase‐2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74: 1095–105
   PubMed Web of Science ®Google Scholar
• Singh G., Fort J. G., Goldstein J. L., Levy R. A., Hanrahan P. S., Bello A. E., , SUCCESS‐I Investigators, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS‐I Study. Am J Med 2006; 119: 255–66
   PubMed Web of Science ®Google Scholar
• Moore R. A., Derry S., Makinson G. T., McQuay H. J. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta‐analysis of information from company clinical trial reports. Arthritis Res Ther 2005; 7: R644–65
   PubMed Web of Science ®Google Scholar
• Silverstein F. E., Faich G., Goldstein J. L., Simon L. S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti‐inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247–55
   PubMed Web of Science ®Google Scholar
• Wolfe F., Michaud K., Burke T. A., Zhao S. Z. Longer use of COX‐2‐specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol 2004; 31: 355–8
   PubMed Web of Science ®Google Scholar
• Zhao S. Z., Wentworth C., Burke T. A., Makuch R. W. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX‐2 specific inhibitors and non‐specific NSAIDs. Pharmacoepidemiol Drug Saf 2004; 13: 277–87
   PubMed Web of Science ®Google Scholar
• McKenna F., Borenstein D., Wendt H., Wallemark C., Lefkowith J. B., Geis G. S. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001; 30: 11–18
   PubMed Web of Science ®Google Scholar
• Emery P., Zeidler H., Kvien T. K., Guslandi M., Naudin R., Stead H., et al. Celecoxib versus diclofenac in long‐term management of rheumatoid arthritis: randomised double‐blind comparison. Lancet 1999; 354: 2106–11
   PubMed Web of Science ®Google Scholar
• Goldstein J. L., Eisen G. M., Burke T. A., Pena B. M., Lefkowith J., Geis G. S. Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. Aliment Pharmacol Ther 2002; 16: 819–27
   PubMed Web of Science ®Google Scholar
• The EuroQol Group. EQ‐5D., Available at: www.euroqol.org/
   Google Scholar
• Rabeneck L. Measuring dyspepsia‐related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX‐2‐specific inhibitors. Rheumatology (Oxford) 2003; 42((Suppl 3))iii32–9
   PubMedGoogle Scholar
• Rabeneck L., Wristers K., Goldstein J. L., Eisen G., Dedhiya S. D., Burke T. A. Reliability, validity, and responsiveness of Severity of Dyspepsia Assessment (SODA) in a randomized clinical trial of a COX‐2‐specific inhibitor and traditional NSAID therapy. Am J Gastroenterol 2002; 97: 32–9
   PubMed Web of Science ®Google Scholar
• LFN (Swedish Pharmaceutical Benefits Board), http://www.lfn.se
   Google Scholar
• Södra Regionvårdsnämnden, Regionala priser och ersättningar 2002 för södra sjukvårdsregionen (MAS), Available at: www.srvn.org
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095–108
   PubMed Web of Science ®Google Scholar
• PhRMA Clinical Study Synopsis, CLASS study. 2006, Available at: www.clinicalstudyresults.org/documents/company‐study_1841_0.pdf
   Google Scholar
• Maddrey W. C., Maurath C. J., Verburg K. M., Geis G. S. The hepatic safety and tolerability of the novel cyclooxygenase‐2 inhibitor celecoxib. Am J Ther 2000; 7: 153–8
   PubMedGoogle Scholar
• Penninx B. W., Pahor M., Woodman R. C., Guralnik J. M. Anemia in old age is associated with increased mortality and hospitalization. J Gerontol A Biol Sci Med Sci 2006; 61: 474–9
   PubMed Web of Science ®Google Scholar
• Penninx B. W., Guralnik J. M., Onder G., Ferrucci L., Wallace R. B., Pahor M. Anemia and decline in physical performance among older persons. Am J Med 2003; 115: 104–10
   PubMed Web of Science ®Google Scholar
• Penninx B. W., Pahor M., Cesari M., Corsi A. M., Woodman R. C., Bandinelli S., et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc 2004; 52: 719–24
   PubMed Web of Science ®Google Scholar
• Chaves P. H., Semba R. D., Leng S. X., Woodman R. C., Ferrucci L., Guralnik J. M., et al. Impact of anemia and cardiovascular disease on frailty status of community‐dwelling older women: the Women's Health and Aging Studies I and II. J Gerontol A Biol Sci Med Sci 2005; 60: 729–35
   PubMed Web of Science ®Google Scholar
• Whelton A., Maurath C. J., Verburg K. M., Geis G. S. Renal safety and tolerability of celecoxib, a novel cyclooxygenase‐2 inhibitor. Am J Ther 2000; 7: 159–75
   PubMedGoogle Scholar
• Whelton A., Lefkowith J. L., West C. R., Verburg K. M. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti‐inflammatory drugs diclofenac and ibuprofen. Kidney Int 2006; 70: 1495–502
   PubMed Web of Science ®Google Scholar
• Bombardier C., Laine L., Reicin A., Shapiro D., Burgos‐Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520–8
   PubMed Web of Science ®Google Scholar
• Bresalier R. S., Sandler R. S., Quan H., Bolognese J. A., Oxenius B., Horgan K., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102
   PubMed Web of Science ®Google Scholar
• Solomon S. D., McMurray J. J., Pfeffer M. A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80
   PubMed Web of Science ®Google Scholar
• Bertagnolli M. M., Eagle C. J., Zauber A. G., Redston M., Solomon S. D., Kim K., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873–84
   PubMed Web of Science ®Google Scholar
• Arber N., Eagle C. J., Spicak J., Racz I., Dite P., Hajer J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885–95
   PubMed Web of Science ®Google Scholar
• Martin B. K., Breitner J. C. S., Evans D., Lyketsos C. G., Meinert C. L., ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled, Alzheimer's Disease Anti‐Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006; 1: e33
   PubMedGoogle Scholar
• White W. B., West C. R., Borer J. S., Gorelick P. B., Lavange L., Pan S. X., et al. Risk of cardiovascular events in patients receiving celecoxib: a meta‐analysis of randomized clinical trials. Am J Cardiol 2007; 99: 91–8
   PubMed Web of Science ®Google Scholar
• White W. B., Faich G., Whelton A., Maurath C., Ridge N. J., Verburg K. M., et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase‐2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425–30
   PubMed Web of Science ®Google Scholar
• El Serag H. B., Graham D. Y., Richardson P., Inadomi J. M. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti‐inflammatory drugs: the use of a nomogram in cost‐effectiveness analysis. Arch Intern Med 2002; 162: 2105–10
   PubMed Web of Science ®Google Scholar
• Zabinski R. A., Burke T. A., Johnson J., Lavoie F., Fitzsimon C., Tretiak R., et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001; 19((Suppl 1))49–58
   PubMed Web of Science ®Google Scholar
• Health Canada. Arthritis in Canada: an ongoing challenge. Health Canada, Ottawa 2003, Cat. no H39‐4/14‐2003E. http://www.phac‐aspc.gc.ca/publicat/ac/pdf/ac_e.pdf
   Google Scholar
• Burke T. A., Zabinski R. A., Pettitt D., Maniadakis N., Maurath C. J., Goldstein J. L. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics 2001; 19((Suppl 1))33–47
   PubMed Web of Science ®Google Scholar
• Maetzel A., Krahn M., Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003; 49: 283–92
   PubMed Web of Science ®Google Scholar
• Spiegel B. M., Targownik L., Dulai G. S., Gralnek I. M. The cost‐effectiveness of cyclooxygenase‐2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003; 138: 795–806
   PubMed Web of Science ®Google Scholar